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We describe a case of epileptic seizures occurring after the use of a COX-2 inhibitor. A 61-year-old man was admitted to our
department because of a generalized tonic-clonic seizure. EEG showed generalized slowdown of the activity. Neuroimaging and
blood samples studies did not evidence alterations, but a careful pharmacological history revealed that the patient had taken the
COX-2 inhibitor etoricoxib to treat lumbago few days before the onset of clinical symptoms. No seizures were reported after
etoricoxib discontinuation and an EEG resulted to be normal two months after this. Conclusion. Knowing the pharmacological
history of a patient is important for understanding the clinical presentation and selecting appropriate treatment.This is, to the best
of our knowledge, the first reported case of generalized seizures associated with the use of COX-2 inhibitors.
1. Introduction
Epileptic seizures can be the consequence of different causes,
including brain lesions, electrolyte or metabolic abnormali-
ties, and adverse drug events.There are diverse pharmacolog-
ical molecules that can induce seizures, including tricyclics,
venlafaxine, bupropion, and isoniazid. To our knowledge,
COX-2 inhibitors have never been included on this list.
2. Case Report
A 61-year-old man arrived to our emergency room suffering
from generalized tonic-clonic seizure followed by confusion
upon awakening. The patient had a history of parossistic
atrial fibrillation and two syncopal episodes due to sick
sinus syndrome. Being so, a pacemaker was implanted and
the patient initiated anticoagulant therapy. In 2009, a fall
provoked a bilateral subdural hematoma which completely
disappeared within six months. At the emergency room, a
cardiological evaluation confirmed that the pacemaker was
working properly and it excluded a cardiogenic syncope.
Moreover, the patient denied sleep deprivation, alcohol
abuse, and illicit drug use. A more detailed pharmacological
history revealed that, during the three days prior to the gen-
eralized tonic-clonic episode, he had taken a COX-2 inhibitor
(etoricoxib 90mg/day) for the first time ever to treat lumbago.
Neurological examination revealed a slight right facio-
brachial hemiparesis and a postural tremor of the right arm,
but, after a couple of hours, the neurological examination
resulted to be normal. A brain CT scan showed an old
ischemic lesion in the left semioval region. Electroencephalo-
gram (EEG) indicated the presence of generalized and non-
specific slowing of electrical activity. Serum examination
did not reveal any electrolyte alterations or other metabolic
abnormalities. MRI could not be performed because of the
presence of the pacemaker, but a brain CT scan performed
on day three did not reveal any new lesions. Subsequently,
levetiracetam 500mg twice a day was started. At one-month
follow-up, the patient was not taking COX-2 inhibitors
anymore, he did not report any seizures, and an EEG showed
normal brain activity. For this, levetiracetam was gradually
reduced and eventually stopped. At six-month follow-up,
no seizures were described and an EEG, the first after the
antiepileptic drug withdrawal, produced normal results. One
year later, the patient was in good health and continued to
report being without seizures.
3. Discussion
Selective COX-2 inhibitors (celecoxib, rofecoxib, valdecoxib,
and etoricoxib) are approved for use in rheumatoid arthritis,
osteoarthritis, and acute pain. These drugs demonstrate at
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least a 200- to 300-fold selectivity for inhibition of COX-2
overCOX-1; this leads to amore powerful effect ondecreasing
inflammation and a minimum toxicity (particularly gastro-
duodenal erosion), because there is no effect on the constitu-
tive COX-1 isoform. From a chemical point of view, selective
COX-2 inhibitors possess 1,2-diarylsubstitution on a central
heterocyclic or carbocyclic ring system with a characteristic
methanesulfonyl, sulfonamido, azido, methanesulfonamide,
or pharmacophore-based tetrazole group on one of the aryl
rings that play a crucial role on COX-2 selectivity. Etoricoxib,
in particular, belongs to the 6-membered core group and, as
other 1,2-diarylpyridine derivatives, it has shown good COX-
2 inhibitor potency and selectivity.
The principal benefit associated with selective COX-2
inhibitors is a production of comparable analgesia and anti-
inflammatory effects to the nonselective NSAIDs, with fewer
symptomatic gastric and duodenal ulcers and a decrease
in gastrointestinal symptoms. Limited data are available
concerning toxicity associated with COX-2 inhibitors outside
the gastrointestinal tract [1]. Some studies have suggested that
theCOX-2 enzymehas a significant role in renal development
and function, so the use of its inhibitor can cause an acute
renal failure. In fact, there is evidence that selective COX-2
inhibitors adversely affect renal function in patients at risk
[2].They can also cause anaphylactoid reaction, cardiovascu-
lar effects, and aseptic meningitis [3]. Regarding etoricoxib,
postmarketing cases of induced immune haemolytic anemia
[4], toxic epidermal necrolysis, and an erythema-multiform-
like eruption have been reported [5].
In our case, in light of medical history and the concomi-
tant use of anticoagulation therapy, the first hypothesis to
exclude was hemorrhagic event. As brain CT ruled out both
hemorrhagic and ischemic diseases, the clinical presentation
suggested the occurrence of a first seizure in an adult. In
fact, the focal symptoms and the global slowdown of brain
electrical activity were secondary to the epileptic event (as
a matter of fact, both improved soon after). No association
of seizure to the patient’s lumbago was found. Limb-shaking
TIAs are unusual, especially upon awakening, and they
generally occur in patients with severe carotid occlusive
disease. This was not the case for our patient. Moreover,
considering that the main blood parameters resulted to be
normal and a malfunction of the pacemaker was excluded,
the clinical manifestation could not have been a nonepileptic
event. As the risk of a recurrent seizure is greater within the
first two years after a first seizure for adults presentingwith an
unprovoked first seizure (21–45%) [6], an epileptic drug was
started with the warning not to take COX-2 inhibitors.
As far as we know, etoricoxib-induced seizures have
not been reported in literature; but, between January 2004
and October 2012, three individuals taking etoricoxib were
reported to have epileptic seizures to the Food and Drug
Administration (FDA).
Few experimental studies on rats have shown an
antiepileptic role of COX-2 inhibitors in reducing seizure-
induced neuroinflammation and neuronal hyperexcitability
[7]. Many medications are known to be associated with
an increased risk of seizures [8], at both therapeutic and
toxic concentrations [9], but the underlying mechanisms are
poorly understood. In fact, drug-induced seizures can occur
as a direct result of altering neural pathways and specific exci-
tatory or inhibitory transmitters and receptors within those
pathways; nevertheless, because of complex interactions, no
single mechanism exists for explaining all cases of drug-
induced seizures. Studies have estimated that 6% of new-
onset seizures and up to 9% of status epilepticus cases are due
to drug toxicity [10]. Phenothiazine, tricyclic antidepressants,
salicylate overdoses, chemotherapeutic agents, baclofen, and
an abrupt withdraw from benzodiazepines or barbiturates
have been clearly linked to seizures [8]. However, a link
between etoricoxib and seizure has never been described,
maybe due to the fact that a biological relation is difficult to
determine.
Despite the fact that the role of inflammatory medi-
ators in the pathogenesis of epilepsy is well known, the
role of prostaglandin in epilepsy continues to be debated.
Prostaglandins, which markedly increase following seizures,
may contribute to epileptogenesis and a reduction of the
seizure threshold [11].
The functions of prostaglandins in epileptogenesis have
been studied; however, the role of COX-2 in epilepsy remains
unclear. Conflicting results have been obtained in labora-
tory settings when treatment with a COX-2 inhibitor was
administered before or after induced seizures. It seems that
COX-2may play an early neuroprotective and late neurotoxic
role following seizures [12]. This bidirectional role could
also be explained by the diversity of prostaglandins (e.g.,
PGD2 exhibits anticonvulsive functions but PGE2 causes
epileptogenesis). In fact, PGE2 synthase activity is tightly
coupled with COX-2. In our case, we can hypothesize that
etoricoxib may have induced an unbalanced production
of prostaglandins (e.g., PGE2) which in turn may have
led to neuronal hyperexcitability by increasing ion channel
permeability or enhancing glutamate release from astrocytes.
In order to document a causal association between
etoricoxib use and seizure, dependency between the twomust
be proven.This can be done by considering any temporal and
dose-response relationship, any replication of findings, bio-
logical plausibility, the exclusion of alternative explanations,
a reduction of the events after the elimination of exposure
to the factor, specificity of the association, and consistency
with current knowledge [13]. In our case, there was an
observed temporal relationship, lack of events after cessation
of exposure to the drug, and an exclusion of alternative expla-
nations. Ethical and clinical considerations did not allow us
to reintroduce etoricoxib to investigate for recurrence.
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